Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vardenafil for Overactive Bladder
NCT00478881Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) and detrusor overactivity comparing Vardenafil with Placebo (2 arms). Primary endpoints: Change From Baseline in Bladder Volume at First Detrusor Contraction at 6 weeks and Change From Baseline in Average Number of Daily Micturitions at 6 weeks. Started Aug 2007; status: completed.
02
Drugs
vardenafil
03
Conditions
overactive bladder (OAB)detrusor overactivity
Beyond the preview
Go deeper on NCT00478881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478881.